Our initial grant application proposed """"""""to synthesize and evaluate novel CBI ligands for the treatment of addiction to methamphetamine (METH)."""""""" The overall research goal was to """"""""""""""""identify CBI antagonists and CBI agonists with low in vivo efficacy"""""""" and included design and synthesis of: 1) novel CBI antagonists with neutral or inverse agonist efficacy including biarylpyrazole and biarylimidazole analogs;and 2) CBI ligands varying in agonist efficacy including i) aminoalkylindole (AAI) ligands based on our CBI agonist prototype AM5983 and ii) biarylether sulfonate (BAS) analogs based on the partial agonist BAY59-3074. To date, we have fulfilled the goals of our initial proposal including synthesis and evaluation of novel CBI ligands from the specified chemical classes as well as in vitro and in vivo evaluation of the most promising compounds. This work has led to the discovery of a new family of CBI neutral antagonists as well as CBI agonists with different efficacies. In the search for """"""""druggable"""""""" CBI partial agonists we also have expanded our scope to include two novel classes of cannabinergic ligands that provided us with promising initial results. During the next five year period we intend to advance our current work so as to move our advanced candidate medications for stimulant addiction into the preclinical pre-IND stage. It is important to note that our successful pre-IND candidate and backup compounds also will be eligible for testing as potentially useful medications for nicotine, as well as methamphetamine, addiction. To accomplish our goals, we will design, synthesize, and characterize later generation neutral CBI antagonists with improved overall pharmacological profiles as potential back-ups for our current class of CBI neutral antagonists. The major effort of optimization will be towards obtaining efficacious and safe IND candidates. This will encompass both pyrazole and imidazole analogs with good brain penetration and enhanced oral bioavailability. We also will develop novel CBI selective agonists with low agonist efficacy. We will continue to optimize the two currently-studied classes of CBI agonists (AAI, BAS) for CB1/CB2 selectivity, low CBI efficacy and druggability profiles and, as well, extend the available SAR to identify druggable candidates from two additional cannabinergic classes (adamantyl cannabinoids and (+)-cannabidiol analogswith absolute stereochemistry opposite of the naturally occurring (-)-cannabidiol. The most promising compounds from these synthesis programs will be further studied to determine their a) in vitro elTicacy and b) relative ability to cross the blood brain barrier. Based on these data, novel ligands will be selected for in vivo studies to determine a) behavioral profiles of action using CBI-mediated hypothermia and operant assays especially designed to identify low-efficacy agonists in rats and monkeys and, for the most advantageous candidates, b) attenuation of methamphetamine's relapse-related effects using drug discrimination and i.v. selfadministration procedures in monkeys.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Method to Extend Research in Time (MERIT) Award (R37)
Project #
Application #
Study Section
Special Emphasis Panel (NSS)
Program Officer
Shih, Ming L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeastern University
Schools of Pharmacy
United States
Zip Code
Paronis, Carol A; Chopda, Girish R; Vemuri, Kiran et al. (2018) Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538. J Pharmacol Exp Ther 364:485-493
Hua, Tian; Vemuri, Kiran; Nikas, Spyros P et al. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature 547:468-471
Hua, Tian; Vemuri, Kiran; Pu, Mengchen et al. (2016) Crystal Structure of the Human Cannabinoid Receptor CB1. Cell 167:750-762.e14
Järbe, Torbjörn U C; Gifford, Roger S; Zvonok, Alexander et al. (2016) [INCREMENT]9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats. Behav Pharmacol 27:211-4
Gueye, Aliou B; Pryslawsky, Yaroslaw; Trigo, Jose M et al. (2016) The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. Int J Neuropsychopharmacol 19:
Schindler, Charles W; Redhi, Godfrey H; Vemuri, Kiran et al. (2016) Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Neuropsychopharmacology 41:2283-93
Thompson, Emily E; Jagielo-Miller, Julia E; Vemuri, V Kiran et al. (2016) CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in rats. J Psychopharmacol 30:482-91
Jacobs, David S; Kohut, Stephen J; Jiang, Shan et al. (2016) Acute and chronic effects of cannabidiol on ??-tetrahydrocannabinol (??-THC)-induced disruption in stop signal task performance. Exp Clin Psychopharmacol 24:320-330
Bowles, Nicole P; Karatsoreos, Ilia N; Li, Xiaosong et al. (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci U S A 112:285-90
Keenan, C M; Storr, M A; Thakur, G A et al. (2015) AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol 172:2406-18

Showing the most recent 10 out of 44 publications